Invitrogen and Genoway to Co-Market RNAi Services

Invitrogen and Genoway will co-market RNAi-related services, the companies said last week.

Under the agreement, Invitrogen will combine its expertise in RNAi research technologies with Genoway's portfolio of transgenesis technologies and RNAi in vivo experience to create a new services platform. The platform will allow RNAi vector design through the creation of RNAi transgenic rodent models.

Both companies will share revenues, Genoway said.

Additional details were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

In Science this week: environmental DNA can help in studies of marine animals, and more.